Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, June 2007, p. 1939-1945, Vol. 51, No. 6
0066-4804/07/$08.00+0 doi:10.1128/AAC.01084-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections
A. K. Meagher,1
J. A. Passarell,1*
B. B. Cirincione,1
S. A. Van Wart,1
K. Liolios,1
T. Babinchak,2
E. J. Ellis-Grosse,2 and
P. G. Ambrose3,4
Cognigen Corporation, Buffalo, New York,1
Wyeth Research, Collegeville, Pennsylvania,2
ICPD/Ordway Institute, Albany, New York,3
School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York4
Received 28 August 2006/
Returned for modification 1 December 2006/
Accepted 7 March 2007
Exposure-response analyses were performed for the microbiological and clinical efficacy of tigecycline in the treatment of complicated skin and skin-structure infections, where Staphylococcus aureus and streptococci are the predominant pathogens. A prospective method was developed to create homogeneous patient populations for PK-PD analyses. Evaluable patients from three clinical trials were pooled for analysis. Patients received a tigecycline 100-mg loading dose/50 mg every 12 h or a 50-mg loading dose/25 mg every 12 h. At the test-of-cure visit, microbiologic and clinical responses were evaluated. Patients were prospectively evaluated and classified into cohorts based on baseline pathogens: S. aureus only (cohort 1), monomicrobial S. aureus or streptococci (cohort 2), two gram-positive pathogens (cohort 3), polymicrobial (cohort 4), or other monomicrobial infections (cohort 5). A prospective procedure for combining cohorts was used to increase the sample size. Logistic regression evaluated steady-state 24-h area under the concentration-time curve (AUC24)/MIC ratio as a predictor of response, and classification and regression tree (CART) analyses were utilized to determine AUC/MIC breakpoints. Analysis began with pooled cohorts 2 and 3, the focus of these analyses, and included 35 patients with 40 S. aureus and/or streptococcal pathogens. CART analyses identified a significant AUC/MIC breakpoint of 17.9 (P = 0.0001 for microbiological response and P = 0.0376 for clinical response). The continuous AUC/MIC ratio was predictive of microbiological response based on sample size (P = 0.0563). Analysis of all pathogens combined decreased the ability to detect exposure-response relationships. The prospective approach of creating homogeneous populations based on S. aureus and streptococci pathogens was critical for identifying exposure-response relationships.
* Corresponding author. Mailing address: Cognigen Corp., 395 Youngs Rd., Buffalo, NY 14221. Phone: (716) 633-3463. Fax: (716) 633-7404. E-mail:
julie.passarell{at}cognigencorp.com
Published ahead of print on 12 March 2007.
Antimicrobial Agents and Chemotherapy, June 2007, p. 1939-1945, Vol. 51, No. 6
0066-4804/07/$08.00+0 doi:10.1128/AAC.01084-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Koomanachai, P., Crandon, J. L., Banevicius, M. A., Peng, L., Nicolau, D. P.
(2009). Pharmacodynamic Profile of Tigecycline against Methicillin-Resistant Staphylococcus aureus in an Experimental Pneumonia Model. Antimicrob. Agents Chemother.
53: 5060-5063
[Abstract]
[Full Text]
-
Zhanel, G. G., Baudry, P. J., Tailor, F., Cox, L., Hoban, D. J., Karlowsky, J. A.
(2009). Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum {beta}-lactamases, AmpC {beta}-lactamases and reduced susceptibility to carbapenems using an in vitro model. J Antimicrob Chemother
64: 824-828
[Abstract]
[Full Text]
-
Nicasio, A. M., Crandon, J. L., Nicolau, D. P.
(2009). In Vivo Pharmacodynamic Profile of Tigecycline against Phenotypically Diverse Escherichia coli and Klebsiella pneumoniae Isolates. Antimicrob. Agents Chemother.
53: 2756-2761
[Abstract]
[Full Text]
-
Koomanachai, P., Kim, A., Nicolau, D. P.
(2009). Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. J Antimicrob Chemother
63: 982-987
[Abstract]
[Full Text]
-
Crandon, J. L., Banevicius, M. A., Nicolau, D. P.
(2009). Pharmacodynamics of Tigecycline against Phenotypically Diverse Staphylococcus aureus Isolates in a Murine Thigh Model. Antimicrob. Agents Chemother.
53: 1165-1169
[Abstract]
[Full Text]
-
Bowker, K. E., Noel, A. R., MacGowan, A. P.
(2008). Pharmacodynamics of Minocycline against Staphylococcus aureus in an In Vitro Pharmacokinetic Model. Antimicrob. Agents Chemother.
52: 4370-4373
[Abstract]
[Full Text]
-
Kelesidis, T., Karageorgopoulos, D. E., Kelesidis, I., Falagas, M. E.
(2008). Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother
62: 895-904
[Abstract]
[Full Text]
-
MacGowan, A. P., on behalf of the BSAC Working Parties on Resistanc,
(2008). Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother
62: ii105-ii114
[Abstract]
[Full Text]
-
Passarell, J. A., Meagher, A. K., Liolios, K., Cirincione, B. B., Van Wart, S. A., Babinchak, T., Ellis-Grosse, E. J., Ambrose, P. G.
(2008). Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections. Antimicrob. Agents Chemother.
52: 204-210
[Abstract]
[Full Text]